123 related articles for article (PubMed ID: 38268917)
21. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
Shah NN; Nagle SJ; Torigian DA; Farwell MD; Hwang WT; Frey N; Nasta SD; Landsburg D; Mato A; June CH; Schuster SJ; Porter DL; Svoboda J
Cytotherapy; 2018 Dec; 20(12):1415-1418. PubMed ID: 30385043
[TBL] [Abstract][Full Text] [Related]
22. Updates on Circulating Tumor DNA Assessment in Lymphoma.
Darrah JM; Herrera AF
Curr Hematol Malig Rep; 2018 Oct; 13(5):348-355. PubMed ID: 30136210
[TBL] [Abstract][Full Text] [Related]
23. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank MJ; Hossain NM; Bukhari A; Dean E; Spiegel JY; Claire GK; Kirsch I; Jacob AP; Mullins CD; Lee LW; Kong KA; Craig J; Mackall CL; Rapoport AP; Jain MD; Dahiya S; Locke FL; Miklos DB
J Clin Oncol; 2021 Sep; 39(27):3034-3043. PubMed ID: 34133196
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.
Miljkovic MD; Melani C; Pittaluga S; Lakhotia R; Lucas N; Jacob A; Yusko E; Jaffe ES; Wilson WH; Roschewski M
Blood Adv; 2021 Oct; 5(20):4198-4210. PubMed ID: 34432874
[TBL] [Abstract][Full Text] [Related]
25. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
26. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
27. Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments.
Ramírez-Chacón A; Betriu-Méndez S; Bartoló-Ibars A; González A; Martí M; Juan M
Front Immunol; 2022; 13():1078003. PubMed ID: 36479103
[TBL] [Abstract][Full Text] [Related]
28. Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells.
Dwivedi A; Karulkar A; Ghosh S; Rafiq A; Purwar R
Front Immunol; 2019; 10():401. PubMed ID: 30906295
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
He J; Zou R; Kang L; Yu L; Wang P; Shao Y; Liang J; Wu D; Jin Z; Qu C
Front Oncol; 2023; 13():1283194. PubMed ID: 38090479
[TBL] [Abstract][Full Text] [Related]
30. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
31. Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients.
Cabel L; Decraene C; Bieche I; Pierga JY; Bennamoun M; Fuks D; Ferraz JM; Lefevre M; Baulande S; Bernard V; Vacher S; Mariani P; Proudhon C; Bidard FC; Louvet C
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30901876
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG-PET/CT.
Fernández S; Cereceda L; Díaz E; Figueroa S; Reguera L; Menéndez V; Solórzano JL; Montalbán C; Estévez M; García JF
EJHaem; 2024 Feb; 5(1):70-75. PubMed ID: 38406538
[TBL] [Abstract][Full Text] [Related]
33. Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma.
Morbelli S; Gambella M; Raiola AM; Ghiggi C; Bauckneht M; Raimondo TD; Lapucci C; Sambuceti G; Inglese M; Angelucci E
J Neuroimaging; 2023; 33(5):825-836. PubMed ID: 37291470
[TBL] [Abstract][Full Text] [Related]
34. Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.
Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
Front Immunol; 2022; 13():1082984. PubMed ID: 36618369
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma.
Dean EA; Kimmel GJ; Frank MJ; Bukhari A; Hossain NM; Jain MD; Dahiya S; Miklos DB; Altrock PM; Locke FL
Blood Adv; 2023 Aug; 7(16):4608-4618. PubMed ID: 37126659
[TBL] [Abstract][Full Text] [Related]
36. Measurement of circulating tumor DNA to guide management of patients with lymphoma.
Sriram D; Lakhotia R; Fenske TS
Clin Adv Hematol Oncol; 2019 Sep; 17(9):509-517. PubMed ID: 31549972
[TBL] [Abstract][Full Text] [Related]
37. Value of CT-Textural Features and Volume-Based PET Parameters in Comparison to Serologic Markers for Response Prediction in Patients with Diffuse Large B-Cell Lymphoma Undergoing CD19-CAR-T Cell Therapy.
Reinert CP; Perl RM; Faul C; Lengerke C; Nikolaou K; Dittmann H; Bethge WA; Horger M
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329846
[TBL] [Abstract][Full Text] [Related]
38. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
[TBL] [Abstract][Full Text] [Related]
39. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Powles T; Young A; Nimeiri H; Madison RW; Fine A; Zollinger DR; Huang Y; Xu C; Gjoerup OV; Aushev VN; Wu HT; Aleshin A; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Schleifman E; Assaf ZJ; Oxnard G; Hegde PS
Front Oncol; 2023; 13():1221718. PubMed ID: 37601688
[TBL] [Abstract][Full Text] [Related]
40. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
